Preclinical models for pediatric solid tumor drug discovery: current trends, challenges and the scopes for improvement

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Expert Opinion on Drug Discovery

• Publication date

  2012-10-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/17460441.2012.722077PMID 22998522
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults.

  2012cited by this paper
• Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma

  2012cited by this paper
• Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma

  2012cited by this paper
• Of dogs and men: Comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma

  2012cited by this paper
• A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma

  2012cited by this paper
• Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells

  2012cited by this paper
• Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21Cip1 expression and hampers tumour cell growth in vitro and in vivo

  2011cited by this paper
• Challenging issues in pediatric oncology

  2011cited by this paper
• Targeting hypoxia in cancer therapy

  2011cited by this paper
• Bortezomib Primes Neuroblastoma Cells for TRAIL-Induced Apoptosis by Linking the Death Receptor to the Mitochondrial Pathway

  2011cited by this paper
• Preclinical Models for Neuroblastoma: Establishing a Baseline for Treatment

  2011cited by this paper
• Transdifferentiation of glioblastoma cells into vascular endothelial cells

  2011cited by this paper
• Preponderance of sonic hedgehog pathway activation characterizes adult medulloblastoma

  2011cited by this paper
• Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor

  2011cited by this paper
• Cancer Stem Cells and Pediatric Solid Tumors

  2011cited by this paper
• Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors.

  2011cited by this paper
• Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a.

  2011cited by this paper
• Preclinical drug development for childhood cancer

  2011cited by this paper
• Homozygous and heterozygous p53 knockout rats develop metastasizing sarcomas with high frequency.

  2011cited by this paper
• Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct

  2011cited by this paper
• Surrogate biomarkers of antiangiogenesis in Children's Oncology Group (COG) phase I trials.

  2011cited by this paper
• Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma

  2011cited by this paper
• PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis

  2011cited by this paper
• Rapamycin Pharmacokinetic and Pharmacodynamic Relationships in Osteosarcoma: A Comparative Oncology Study in Dogs

  2010cited by this paper
• Targeting the osteosarcoma cancer stem cell

  2010cited by this paper
• Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.

  2010influential reference
• A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A Children's Oncology Group study

  2010cited by this paper
• CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance.

  2010cited by this paper
• Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma

  2010cited by this paper
• Treating retinoblastoma in tissue culture and in a rat model with a novel isoquinoline derivative.

  2010cited by this paper
• Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease.

  2010influential reference
• Pediatric and wild-type gastrointestinal stromal tumor: new therapeutic approaches

  2010cited by this paper
• Effects of bone morphogenetic protein 2 on Id expression and neuroblastoma cell differentiation.

  2010cited by this paper
• Cancer research in rat models.

  2010cited by this paper
• Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma

  2010cited by this paper
• Phase I Pharmacokinetic and Pharmacodynamic Evaluation of Combined Valproic Acid/Doxorubicin Treatment in Dogs with Spontaneous Cancer

  2010cited by this paper
• Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients.

  2009cited by this paper
• Proteomic analysis of neuroblastoma microenvironment: effect of the host-tumor interaction on disease progression.

  2009cited by this paper
• Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

  2009cited by this paper
• Tumour-initiating cells: challenges and opportunities for anticancer drug discovery

  2009cited by this paper
• Tumor initiating cells in malignant gliomas: biology and implications for therapy

  2009cited by this paper
• Direct In Vivo Xenograft Tumor Model for Predicting Chemotherapeutic Drug Response in Cancer Patients

  2009cited by this paper
• A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.

  2009cited by this paper
• Guiding the Optimal Translation of New Cancer Treatments From Canine to Human Cancer Patients

  2009cited by this paper
• Clinical Drug Development for Childhood Cancers

  2009cited by this paper
• A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study

  2008cited by this paper
• Molecular Characterization of the Pediatric Preclinical Testing Panel

  2008cited by this paper
• Mouse xenograft models vs GEM models for human cancer therapeutics

  2008cited by this paper
• Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma.

  2008cited by this paper
• Detection and Characterization of CD133+ Cancer Stem Cells in Human Solid Tumours

  2008cited by this paper
• Apoptotic genes as potential markers of metastatic phenotype in human osteosarcoma cell lines.

  2008cited by this paper
• Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models

  2008cited by this paper
• Microsatellites as EWS/FLI response elements in Ewing's sarcoma

  2008cited by this paper
• Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.

  2008cited by this paper
• Hypoxia Enhances Tumor Stemness by Increasing the Invasive and Tumorigenic Side Population Fraction

  2008cited by this paper
• In vivo three-dimensional high-resolution imaging of rodent retina with spectral-domain optical coherence tomography.

  2007cited by this paper
• The pediatric preclinical testing program: Description of models and early testing results

  2007cited by this paper
• Dose translation from animal to human studies revisited

  2007cited by this paper
• Tissue microenvironment modulates CXCR4 expression and tumor metastasis in neuroblastoma.

  2007cited by this paper
• Tumor origin of endothelial cells in human neuroblastoma.

  2007cited by this paper
• Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis.

  2007cited by this paper
• Activation of Akt predicts poor outcome in neuroblastoma.

  2007cited by this paper
• Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

  2007cited by this paper
• The first knockout mouse model of retinoblastoma.

  2006cited by this paper
• Using Genetically Engineered Mouse Models of Cancer to Aid Drug Development: An Industry Perspective

  2006cited by this paper
• The Use of Targeted Mouse Models for Preclinical Testing of Novel Cancer Therapeutics

  2006cited by this paper
• Rat Models of Bone Metastases

  2006cited by this paper
• Genetically engineered models have advantages over xenografts for preclinical studies.

  2006influential reference
• The multifaceted circulating endothelial cell in cancer: towards marker and target identification

  2006cited by this paper
• Little patients, losing patience: pediatric cancer drug development

  2006cited by this paper
• Low-dose Methotrexate Inhibits Lung Metastasis and Lengthens Survival in Rat Osteosarcoma

  2005cited by this paper
• Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma.

  2005cited by this paper
• A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies

  2004cited by this paper
• CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases.

  2004cited by this paper
• Anticancer Drug Development: Preclinical Screening, Clinical Trials and Approval

  2004cited by this paper
• Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

  2004cited by this paper
• Can mouse models for brain tumors inform treatment in pediatric patients?

  2004cited by this paper
• Bone morphogenetic proteins in bone tumors

  2004cited by this paper
• Survivin expression in childhood medulloblastomas: a possible diagnostic and prognostic marker.

  2004cited by this paper
• Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice

  2004cited by this paper
• In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia.

  2004influential reference
• Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans: Better than Commonly Perceived—But They Can Be Improved

  2003cited by this paper
• Study of proliferation and apoptosis in neuroblastoma. Their relation with other prognostic factors.

  2002cited by this paper
• Mechanisms of cancer drug resistance.

  2002cited by this paper
• Increased susceptibility of copper-deficient neuroblastoma cells to oxidative stress-mediated apoptosis.

  2001cited by this paper
• Why drugs fail: of mice and men revisited.

  2001cited by this paper
• A novel metastatic animal model reflecting the clinical appearance of human neuroblastoma: growth arrest of orthotopic tumors by natural, cytotoxic human immunoglobulin M antibodies.

  2001cited by this paper
• The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma.

  2001cited by this paper
• Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children.

  1999cited by this paper
• Efficacy and Concentration-Response of Murine Anti-VEGF Monoclonal Antibody in Tumor-Bearing Mice and Extrapolation to Humans

  1999cited by this paper
• Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995.

  1999cited by this paper
• Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors.

  1998cited by this paper
• Animal model of human medulloblastoma: clinical, magnetic resonance imaging, and histopathological findings after intra-cisternal injection of MHH-MED-1 cells into nude rats.

  1997cited by this paper
• Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro

  1997cited by this paper
• Disseminated neuroblastoma in the nude rat: A xenograft model of human malignancy

  1996cited by this paper

• Advances in emerging drugs for the treatment of neuroblastoma

  2017cites this paper
• Sulforaphene–Carboplatin Combination Synergistically Enhances Apoptosis by Disruption of Mitochondrial Membrane Potential and Cell Cycle Arrest in Human Non-Small Cell Lung Carcinoma

  2016cites this paper
• Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer—Evidence for a Relevant Model System and Urine-Based Diagnostic Test

  2015cites this paper
• The human peroxisome in health and disease: the story of an oddity becoming a vital organelle.

  2014cites this paper
• TRAIL-based therapeutic approaches for the treatment of pediatric malignancies.

  2013cites this paper